Condition: Sarcoma,Soft Tissue · Sponsor: Swiss Cancer Institute
Soft tissue sarcomas (STSs) are rare cancers with a 5-year survival rate of 60%, and there is no standard treatment for high-risk extremity and trunk STSs (eSTS). A phase III trial suggests that adding moderate regional hyperthermia (HT) to anthracycline-based chemotherapy, followed by surgery and radiotherapy (RT), can improve 10-year overall survival by 10%. This trial aims to optimize treatment by combining the most effective regimens from chemotherapy, HT, RT, and surgery, and will evaluate the feasibility of this new total neoadjuvant treatment (TNT) approach.
This description comes directly from the study's public registry record.
Gwendoline Wicki · +41 31 389 91 91 · trials@sakk.ch
Always discuss trial participation with your own doctor first.
| Kantonsspital Aarau | Aarau, Switzerland | Recruiting |
| Universitaetsspital Basel | Basel, Switzerland | Recruiting |
| EOC - Istituto Oncologico della Svizzera Italiana | Bellinzona, Switzerland | Recruiting |
| Inselspital Bern - Universitätsklinik für Radioonkologie | Bern, Switzerland | Recruiting |
| CHUV - Swiss Cancer Center Lausanne | Lausanne, Switzerland | Recruiting |
| hoch Health Ostschweiz - Kantonsspital St. Gallen | Sankt Gallen, Switzerland | Recruiting |
| Kantonsspital Winterthur | Winterthur, Switzerland | Recruiting |
| Universitätsspital Zürich | Zurich, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06835049